Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis

医学 抗体 脑炎 自身免疫性脑炎 化学 免疫学 病毒学 生物化学 受体 病毒 自身抗体
作者
Margherita Nosadini,Michael Eyre,Erika Molteni,Terrence Thomas,Sarosh R. Irani,Josep Dalmau,Russell C. Dale,Ming Lim,International NMDAR Antibody Encephalitis Consensus Group,Banu Anlar,Thaís Armangué,Susanne M. Benseler,Tania Cellucci,Kumaran Deiva,William B. Gallentine,Grace Gombolay,Mark Gorman,Yael Hacohen,Yuwu Jiang,Byung Chan Lim
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:78 (11): 1333-1333 被引量:223
标识
DOI:10.1001/jamaneurol.2021.3188
摘要

Importance: Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments and combinations remains unclear. Objective: To map the use and safety of immunotherapies in individuals with NMDARE, identify early predictors of poor functional outcome and relapse, evaluate changes in immunotherapy use and disease outcome over the 14 years since first reports of NMDARE, and assess the Anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score. Data Sources: Systematic search in PubMed from inception to January 1, 2019. Study Selection: Published articles including patients with NMDARE with positive NMDAR antibodies and available individual immunotherapy data. Data Extraction and Synthesis: Individual patient data on immunotherapies, clinical characteristics at presentation, disease course, and final functional outcome (modified Rankin Scale [mRS] score) were entered into multivariable logistic regression models. Main Outcomes and Measures: The planned study outcomes were functional outcome at 12 months from disease onset (good, mRS score of 0 to 2; poor, mRS score greater than 2) and monophasic course (absence of relapse at 24 months or later from onset). Results: Data from 1550 patients from 652 articles were evaluated. Of these, 1105 of 1508 (73.3%) were female and 707 of 1526 (46.3%) were 18 years or younger at disease onset. Factors at first event that were significantly associated with good functional outcome included adolescent age and first-line treatment with therapeutic apheresis, corticosteroids plus intravenous immunoglobulin (IVIG), or corticosteroids plus IVIG plus therapeutic apheresis. Factors significantly associated with poor functional outcome were age younger than 2 years or age of 65 years or older at onset, intensive care unit admission, extreme delta brush pattern on electroencephalography, lack of immunotherapy within the first 30 days of onset, and maintenance IVIG use for 6 months or more. Factors significantly associated with nonrelapsing disease were rituximab use or maintenance IVIG use for 6 months or more. Adolescent age at onset was significantly associated with relapsing disease. Rituximab use increased from 13.5% (52 of 384; 2007 to 2013) to 28.3% (311 of 1100; 2013 to 2019) (P < .001), concurrent with a falling relapse rate over the same period (22% [12 of 55] in 2008 and earlier; 10.9% [35 of 322] in 2017 and later; P = .006). Modified NEOS score (including 4 of 5 original NEOS items) was associated with probability of poor functional status at 1 year (20.1% [40 of 199] for a score of 0 to 1 points; 43.8% [77 of 176] for a score of 3 to 4 points; P = .05). Conclusions and Relevance: Factors influencing functional outcomes and relapse are different and need to be considered independently in development of evidence-based optimal management guidelines of patients with NMDARE.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
百里丹珍完成签到,获得积分10
1秒前
洋芋二号发布了新的文献求助10
1秒前
传奇3的应助被四辈采纳,获得10
1秒前
NexusExplorer的应助被汤汤采纳,获得10
2秒前
听枫完成签到,获得积分10
2秒前
yong完成签到,获得积分10
3秒前
Jiaaaa完成签到,获得积分10
3秒前
HEH发布了新的文献求助10
3秒前
hou的应助被尾气是菠萝口味采纳,获得10
4秒前
张津浩完成签到,获得积分10
4秒前
深情的依风完成签到,获得积分10
4秒前
依壹完成签到,获得积分10
4秒前
张铁柱完成签到,获得积分10
4秒前
Cakoibao的应助被ZYC007采纳,获得10
4秒前
花开富贵完成签到,获得积分10
4秒前
赵丽莹完成签到,获得积分10
5秒前
Poisomber完成签到,获得积分10
5秒前
5秒前
李李玲发布了新的文献求助10
5秒前
化学学渣完成签到,获得积分10
5秒前
GGbond完成签到,获得积分10
6秒前
samxie完成签到,获得积分10
6秒前
泽雾川完成签到,获得积分10
6秒前
txinlanc完成签到,获得积分10
6秒前
青橙发布了新的文献求助20
7秒前
研友_Lw7MKL完成签到,获得积分10
7秒前
早起完成签到,获得积分10
7秒前
王春来完成签到,获得积分10
8秒前
Broxiga完成签到,获得积分10
8秒前
研友_VZG7GZ的应助被整齐的手机采纳,获得10
8秒前
BAEKHYUNLUCKY完成签到,获得积分10
8秒前
小海绵发布了新的文献求助10
9秒前
komorebi完成签到,获得积分10
9秒前
华仔的应助被呜呼采纳,获得10
9秒前
俏皮秋烟完成签到,获得积分10
9秒前
冀晓梦完成签到,获得积分10
10秒前
纳米酶催化完成签到,获得积分10
10秒前
10秒前
10秒前
gefan完成签到 ,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152197
求助须知:如何正确求助?哪些是违规求助? 9548933
关于积分的说明 21688809
捐赠科研通 7740419
什么是DOI,文献DOI怎么找? 3425136
关于科研通互助平台的介绍 2550342
邀请新用户注册赠送积分活动 2468584